Corona Virus White Paper

White Paper

Can The Coronavirus Contagion Economically Infect The Global Pharmaceutical Industry?

Events surrounding the coronavirus contagion, characterized as a “black swan” event, which started in China, remain very fluid and are changing daily. No one really knows what ...

Importation of Drugs

White Paper

Importation Of Drugs Is Back Again On The Pharma Public Policy Table – A Short Commentary

This commentary white paper provides reasons why importation is still a bad idea today, but more importantly, why the reintroduction of this policy is a reflection of the broader e ...

AstraZeneca’s Bold And Potentially Risky New Cancer Drug R&D Portfolio Strategy

White Paper

AstraZeneca’s Bold And Potentially Risky New Cancer Drug R&D Portfolio Strategy

This paper explores the challenges and opportunities this new strategy can have for AstraZeneca while providing other pharma companies that are contemplating a similar different R& ...

US Recession Pharma Analytics

White Paper

How Will The Next Great Recession Affect The US Pharma Industry?

The US will have another recession as certain as night follows day. The business cycle has not been outlawed nor made extinct, contrary to the overly optimistic views of macroecono ...

Merger and Acquisitions

White Paper

Do Pharma Mergers And Acquisitions Improve R&D Productivity And Increase Shareholder Value?

Mergers & acquisitions (M&As) have long been used as a critical strategic instrument by pharmaceutical company executives to spur R&D innovation, sustain financial grow ...

Future of Pharma - Evolving Commercial Models

Report

Future Of Pharma: Evolving Commercial Models – Part 2

Learn what several senior pharma commercial operations leaders think of the potential implications of industry challenges on business operations, sales and marketing objectives and ...

Politics ‘Trumps’ Rational Policy Rule Change On Ending Rebates To PBMs For The Medicare Program

White Paper

Politics ‘Trumps’ Rational Policy Rule Change On Ending Rebates To PBMs For The Medicare Program

This paper explores the reason behind this about-face, potential policy alternatives President Trump may pursue to reduce drug prices and their adverse consequences, and what shoul ...

Future of Pharma - Evolving Commercial Models

Report

Future Of Pharma: Evolving Commercial Models – Part 1

The pharmaceutical industry is in a state of flux with the increasing influence of payers, pressure from the government with restricted healthcare budgets, and the rise of multi-ch ...

PBMs Pharma Benefit Manager

White Paper

Proposed Rule To End Rebates To PBMs For Medicare And Medicaid Programs

This white paper looks at how rebates to PBMs relate to drug prices from two perspectives: how they are supposed to work versus what actually happens. ...

Start typing and press Enter to search